CONSHOHOCKEN, Pa. – June 30, 2025 – AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, today announced that it has closed on the previously disclosed disposition of certain infusion assets in its Wellness at Home segment to a third party. The transaction was completed earlier this month.
“The disposition of certain infusion assets marks yet another significant step in our effort to sharpen our strategic focus by exiting ancillary product lines,” said AdaptHealth CEO, Suzanne Foster. “Additionally, the sale advances our commitment to debt reduction to unlock value for our shareholders.”
The Company used the proceeds of the disposition, and other funds, to make a prepayment of $65.0 million on its outstanding term loan. This prepayment was in addition to a previously announced $70.0 million prepayment on the term loan in May, funded primarily with proceeds from the sale of certain incontinence assets.
The products included in the disposition of certain infusion assets represented approximately $52 million of annual revenue and approximately $5 million of annual Adjusted EBITDA. Additionally, the Company projects $30 million of cash taxes due on the gains from this disposition. To reflect these impacts, the Company is revising its full-year revenue guidance to a range of $3,150 million to $3,290 million, its full-year 2025 Adjusted EBITDA to a range of $662 million to $702 million, and its full-year 2025 Free Cash Flow to a range of $170 million to $190 million.
Download the Press Release Here